• Explore /
  • Poster
  • / BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

Abstract Video & Slides Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Johanna C. Bendell , Judy Sing-Zan Wang , Babar Bashir , Debra L. Richardson , Gavin Bennett , Carly Campbell , Meliessa G. Hennessy , Phil Jeffrey , Julius Kirui , Lisa Mahnke , Geoffrey Shapiro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04180371

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3655)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3655

Abstract #

TPS3655

Poster Bd #

385

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).

First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).

First Author: Jacob M. Sands

First Author: David S. Hong

First Author: Anna Rachel Minchom

First Author: Manish Sharma